Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IV [14C]-GSK3191607 in Healthy Males
NCT02737007Phase 1Completed
- Sponsor
- GSK
- Start
- Apr 2016
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gsk3191607 in Malaria, sponsored by GSK. Primary endpoints: Maximum observed concentration at 336 hours, Terminal phase half life at 336 hours and 11 more. Started Apr 2016; status: completed.
02
Drugs
gsk3191607
03
Conditions
Malaria
Beyond the preview
Go deeper on NCT02737007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737007.